Histone deacetylase inhibitors: Mechanism of action and therapeutic use in cancer

Clinical and Translational Oncology

Volumn 10, Issue 7, 2008, Pages 395-398

  Martínez Iglesias, Olaia ^a   Ruiz Llorente, Lidia ^a   Sánchez Martínez, Ruth ^a   García, Laura ^a   Zambrano, Alberto ^a   Aranda, Ana ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Combination therapy; Histone deacetylase inhibitors; Histone deacetylases

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; HUMAN; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; GENE EXPRESSION; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 53749087120     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0221-x     Document Type: Article

References (30)

1. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074-
2. Riggs MG, Whittaker RG, Neumann JR, Ingram VM (1977). n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268(5619):462-464
3. Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12 (5):599-606
4. Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74(5):659-671
5. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14(12):1497-1511
6. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435
7. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981-989
8. Fischle W, Dequiedt F, Hendzel MJ et al (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9(1):45-57
9. Li J, Wang J, Wang J et al (2000) Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. Embo J 19 (16):4342-4350
10. Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4):391-400
11. Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26(37):5420-5432
12. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784
13. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38-51
14. Rosato RR, Grant S (2005) Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9(4):809-824
15. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25(1):84-90
16. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28):17174-17179
17. Richon VM, Emiliani S, Verdin E et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95(6):3003-3007
18. Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-39
19. Hu E, Dul E, Sung CM et al (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307 (2):720-728
20. Haggarty SJ, Koeller KM, Wong JC et al (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100(8): 4389-4394
21. Peart MJ, Smyth GK, van Laar RK et al (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102(10):3697-3702
22. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37):5541-5552
23. Gui CY, Ngo L, Xu WS et al (2004) Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101(5):1241-1246
24. Insinga A, Monestiroli S, Ronzoni S et al (2005) Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat Med 11(1):71-76
25. Ruefli AA, Ausserlechner MJ, Bernhard D et al (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98(19):10833-10838
26. Kim MS, Kwon HJ, Lee YM et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4): 437-443
27. Mori T, Kim J, Yamano T et al (2005) Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65(5):1800-1807
28. Whetstine JR, Ceron J, Ladd B et al (2005) Regulation of tissue-specific and extracellular matrixrelated genes by a class I histone deacetylase. Mol Cell 18(4):483-490
29. Karagiannis TC, El-Osta A (2006) Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 1(3):121-126
30. US National Institutes of Health, US National Library of Medicine (2008). www.clinicaltrials.gov. Accessed